Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q1 2018 Earnings Presentation

11 slides from Lumos Pharma's earnings presentation, May 3, 2018

  1. Slide 1: First Quarter 2018 Financial Results

    NewLink Genetics Corporation Nasdaq: NLNK May 3, 2018 First Quarter 2018 Financial Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments & Outlook  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates & Guidance on Timing of Data  Eugene P. Kennedy, M.D., Chief Medical Officer First Quarter 2018 Financial Results  Jac

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,

  4. Slide 4: Recent Highlights

    Recent Highlights  Presented two abstracts at AACR Annual Meeting, April 2018 – Abstract 3753 – Indoximod modulates AhR-driven transcription of genes that control immune function – Abstract 10973 – Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation an

  5. Slide 5: Upcoming Milestones 2018

    Upcoming Milestones 2018  Abstracts accepted for presentation at ASCO Annual Meeting, June 2018 – Abstract 9512 – Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma – Abstract 4015 – Phase 2 trial of the IDO pathway i

  6. Slide 6: Indoximod Mechanism of Action

    Indoximod Mechanism of Action A Unique Approach to Reversing Immunosuppression 6  Indoximod is an orally administered, small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan and high kynurenine that result from IDO activity  Indoximod has immunostimulato

  7. Slide 7: Indoximod vs Epacadostat: A Different Mechanism of Action

    Indoximod vs Epacadostat: A Different Mechanism of Action Indoximod Drives Differentiation of Helper vs Regulatory T Cells 7 -1 0 1 2 3 0 2 0 4 0 6 0 8 0 1 0 0 0 2 0 4 0 6 0 8 0 1 0 0 L o g [ In d o x im o d ] (µ M ) % f o x p 3 + a m o n g C D 4 + C D 2 5 + c e ll s % IL -1 7 + a m o n g C D 4 + c

  8. Slide 8: Encouraging Early Results for Patients with Newly Diagnosed DIPG

    Encouraging Early Results for Patients with Newly Diagnosed DIPG 8  Example of significant response in 9.4-yr-old patient . Johnson T, et al. AACR 2018. Plenary #10973.

  9. Slide 9: Financial Position

    Financial Position Q1 2018 End Cash and Equivalents $143.9 million YE 2018 Cash Projected To be updated on Q2 call Shares Outstanding as of March 31, 2018 37.2 Million 9

  10. Slide 10: NewLink Genetics: Key Takeaways

    NewLink Genetics: Key Takeaways Indoximod, an Immuno-oncology Candidate with Differentiated MOA  Indoximod has a differentiated mechanism of action (MOA)  Reverses the effects of low tryptophan by increasing proliferation of effector T cells  Drives differentiation into T helper cells vs regulato

  11. Slide 11: Q & A

    11 Q & A

NewLink Genetics — Q1 2018 Earnings Presentation on 6ix